Focal Brachytherapy
Download
1 / 27

Prof Stephen Langley - PowerPoint PPT Presentation


  • 137 Views
  • Uploaded on

Focal Brachytherapy UK experience. Prof Stephen Langley. Professor of Urology St Luke’s Cancer Centre, Guildford, UK PGMS, University of Surrey. Is there a problem?. Prostate Cancer Focality. 13-38% cancer are unifocal.

loader
I am the owner, or an agent authorized to act on behalf of the owner, of the copyrighted work described.
capcha
Download Presentation

PowerPoint Slideshow about ' Prof Stephen Langley' - hammett-bentley


An Image/Link below is provided (as is) to download presentation

Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author.While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server.


- - - - - - - - - - - - - - - - - - - - - - - - - - E N D - - - - - - - - - - - - - - - - - - - - - - - - - -
Presentation Transcript
Prof stephen langley

Focal Brachytherapy

UK experience

Prof Stephen Langley

Professor of Urology

St Luke’s Cancer Centre, Guildford, UK

PGMS, University of Surrey



Prostate cancer focality
Prostate Cancer Focality

  • 13-38% cancer are unifocal.

  • Of multifocal tumours, in 97% the Gleason grade of the index tumour was the same as the grade of the overall cancer.

  • PFS relates to index tumour volume not secondary tumour Stamey, Urology 2002

  • Multifocal tumours, 80% of the total volume arises from the index lesion.

  • 512/1832 (28%) of RP patients ECE was evident with 92% of extensions from the index lesion.

  • In low risk PAC, 28% unifocal lesions with 1% showing EPE.

Arora et al, Cancer 2004

Ohori et al, J Urol 2006


Prof stephen langley

Prostate Cancer Focality

  • Multiple studies have suggested that non-index lesions have little if any clinical significance

Noguci et al, J Urol 2003

Karavitakis et al, Nat Rev Clin Onc 2011

Mouraviev et al, BJUInt 2011


Ideal for focal therapy
Ideal for Focal Therapy:

BXT

Eggener et al, J Urol 2007, 178 2260

  • Tumour-cidal activity throughout target zone

  • Real-time monitoring

  • Minimal-access approach to gland

  • Minimal collateral effects outside treatment focus

  • Cost effective

  • Allows re-treatment or subsequent whole gland radical treatment


Terminology focal bxt
Terminology: Focal BXT

  • CTV: Whole gland plus 3mm margin

  • F-GTV: Gross visible/detectable tumour

  • F-CTV: F-GTV + clinically insignificant disease

  • F-PTV : F-CTV + planning margin to allow for uncertainties in treatment delivery

Focal

Ultra-Focal


Imaging
Imaging

Preferred Imaging modality, mpMRI

  • T1/T2, Diff weighting, DCE

  • For 0.5ml tumour NPV 95%, PPV 77%

    Sens. 90%, Spec. 88%

Villers A, et al.J Urol 2006; 176:





Prof stephen langley

N=21

Clinical & MRI staging T1c-T2a

PSA<10, Vol <75cc

Unilateral Gleason ≤3+4

No core <50% cancer

<25% cores involved

>20 Biopsy cores taken

Real-time technique, loose seeds

Ultra-focal approach, using mpMRI & biopsy map

Mean Vol R 34% (20-48)

Uniform seed distribution

F-PTV 145Gy, no CT

PSA FU-(Phoenix), MRI & Biopsy 1-2yrs


Prof stephen langley

Mean IPSS


Prof stephen langley

Mean PSA

Yrs


Prof stephen langley
A Prospective Stage 2S Clinical Trial Evaluating Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer

Hemi-Ablative Prostate Brachytherapy (HAPpy)

1o Objectives

  • To determine if focal brachytherapy shows improved rates of toxicity compared to whole-gland LDR brachytherapy.

  • To determine if focal brachytherapy is associated with similar local disease control rates as whole-gland LDR brachytherapy for low and intermediate prostate cancer.


Prof stephen langley
A Prospective Stage 2S Clinical Trial Evaluating Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer

2o Objectives

  • To histologically assess the untreated prostate at 2-years post hemi-ablative treatment.

  • To determine the clinical validity of mp-MRI to predict the presence of recurrent prostate cancer on TTB biopsies.

  • To assess the value of serum PSA & urinary EN2 in predicting clinical outcome


Prof stephen langley
A Prospective Stage 2S Clinical Trial Evaluating Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer

  • Patient Eligibility

  • TRUS Bx (if taken): unilateral disease only

  • mp-MRI

  • Targeted template biopsy (TTB):

    • unilateral disease only, &

    • Gleason < 7 (either 3+4 or 4+3)

  • Stage T1-T2b N0 M0

  • Serum PSA < 15

  • Prostate volume < 50cc

  • Life expectancy > 10 years

  • No previous radiation therapy

  • No previous hormone treatment


  • Prof stephen langley
    A Prospective Stage 2S Clinical Trial Evaluating Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer


    Prof stephen langley

    Sponsor: NHS R&D RSCH Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer

    LREC: Approved Jan 2013


    Prof stephen langley

    F Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer

    Brachytherapy

    Brachytherapy

    • Simple clinic U/S (H , W , L3).

    • Nomogram calculation of seed requirement.

    • Preloaded stranded seeds implanted peripherally.

    • Real-time planning.

    • Loose seeds implanted centrally.

    • 4thD: Average 40 min per implant.


    Prof stephen langley

    F Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer

    Brachytherapy

    Stranded seed, 1cm spacing

    Loose seed, variable spacing

    CTV

    FPTV

    PTV

    FCTV


    Prof stephen langley
    A Prospective Stage 2S Clinical Trial Evaluating Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer

    Follow up

    • Day 0 CT

    • PSA, EN2, MHI:

      3, 6 ,9, 12, 18, 24m

    • 24m mpMRI

    • 24m TTB of untreated side

    • Standard follow up


    To date
    To date …. Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer


    Prof stephen langley

    Financial Disclosures Hemi-Ablative (LDR) Brachytherapy for Localised Prostate Cancer